| Q35553393 | 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. |
| Q36890646 | 12/15-Lipoxygenase mediates high-fat diet-induced endothelial tight junction disruption and monocyte transmigration: a new role for 15(S)-hydroxyeicosatetraenoic acid in endothelial cell dysfunction |
| Q37536561 | 14,15-EET induces the infiltration and tumor-promoting function of neutrophils to trigger the growth of minimal dormant metastases |
| Q33722731 | 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Src-mediated Egr-1-dependent rapid induction of FGF-2 expression. |
| Q35063134 | 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall re |
| Q36821881 | A review on angiogenesis and its assays |
| Q35958442 | Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells |
| Q35063138 | Activation of cytosolic phospholipase A2 downstream of the Src-phospholipase D1 (PLD1)-protein kinase C γ (PKCγ) signaling axis is required for hypoxia-induced pathological retinal angiogenesis |
| Q35314659 | Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation |
| Q24653023 | Arachidonic acid cytochrome P450 epoxygenase pathway |
| Q51709663 | CYP2J2 - regulation, function and polymorphism. |
| Q28307304 | CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET) |
| Q42580116 | Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. |
| Q37733656 | Cytochrome P450 2C8 ω3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report |
| Q28245279 | Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism |
| Q28393303 | Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation |
| Q34143118 | Cytochrome P450-derived eicosanoids: the neglected pathway in cancer |
| Q34667764 | Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo |
| Q23913301 | Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis |
| Q28250730 | EET signaling in cancer |
| Q35803714 | Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition |
| Q38898133 | Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles |
| Q28396313 | Epoxides and soluble epoxide hydrolase in cardiovascular physiology |
| Q36782159 | Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis |
| Q33904690 | Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function |
| Q91950315 | Frankincense and myrrh and their bioactive compounds ameliorate the multiple myeloma through regulation of metabolome profiling and JAK/STAT signaling pathway based on U266 cells |
| Q33848248 | Glucose intolerance and impaired insulin secretion in pancreas-specific signal transducer and activator of transcription-3 knockout mice are associated with microvascular alterations in the pancreas |
| Q45611249 | Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits |
| Q34157821 | Implication of transient receptor potential vanilloid type 1 in 14,15-epoxyeicosatrienoic acid-induced angiogenesis |
| Q28393594 | Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling |
| Q54979523 | MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway. |
| Q38175461 | Modulation of cardiac cytochrome P450 in patients with heart failure. |
| Q92105332 | New Lipid Mediators in Retinal Angiogenesis and Retinopathy |
| Q36212445 | Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis |
| Q39450755 | P-450-dependent epoxygenase pathway of arachidonic acid is involved in myeloma-induced angiogenesis of endothelial cells |
| Q34122706 | PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. |
| Q26864661 | Peroxisome proliferator-activated receptors in regulation of cytochromes P450: new way to overcome multidrug resistance? |
| Q39584927 | Phosphatidylinositol 3'-kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor-1(alpha) and vascular endothelial growth factor expression |
| Q36908857 | Plasma 12- and 15-hydroxyeicosanoids are predictors of survival in pulmonary arterial hypertension |
| Q38282100 | Potency of non-steroidal anti-inflammatory drugs in chemotherapy. |
| Q28391138 | Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo |
| Q37787958 | Regulation of endothelial cell functions by basement membrane‐ and arachidonic acid‐derived products |
| Q37960812 | Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease |
| Q34681312 | Role for miR-204 in human pulmonary arterial hypertension |
| Q38100223 | Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. |
| Q42378504 | Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer |
| Q37014713 | Roles of the epoxygenase CYP2J2 in the endothelium. |
| Q38260257 | Significance of MTA1 in the molecular characterization of osteosarcoma |
| Q28384279 | Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney |
| Q24597172 | Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases |
| Q28395004 | Soluble epoxide hydrolase in atherosclerosis |
| Q28565946 | Src-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration |
| Q28304230 | Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer |
| Q45968882 | Synthesis of cyclooxygenase metabolites of 8,9-epoxyeicosatrienoic acid (EET): 11- and 15-hydroxy 8,9-EETs. |
| Q54188941 | Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. |
| Q37237506 | The 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Janus kinase 2-signal transducer and activator of transcription-5B-dependent expression of interleukin-8. |
| Q99237540 | The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPARγ/STAT1 Signaling Pathway |
| Q33800226 | The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated |
| Q37947082 | The cytochrome P450 pathway in angiogenesis and endothelial cell biology. |
| Q33901500 | The role of cytochrome P450 epoxygenases in retinal angiogenesis |
| Q64097664 | Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor |
| Q36374238 | ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases. |